Abstract
Interleukin (IL)-1α and IL-1β are proinflammatory cytokines that play a role in many diseases such as rheumatoid arthritis, juvenile rheumatoid arthritis, gout, and periodic inflammatory syndromes, including familial Mediterranean fever and Muckle-Wells syndrome. Drugs targeting IL-1 such as recombinant IL-1Ra (anakinra), neutralizing anti-IL-1β antibodies (canakinumab) and IL-1β traps (rilonacept) are in clinical use to treat these diseases. Additionally, experimental evidence suggests a role of IL-1 in kidney disease and hypertension and targeting IL-1 showed promising results in high cardiovascular risk patients, hemodialysis and renal transplantation patients. We now summarize knowledge on the potential role of IL-1 targeting in patients with kidney disease.
MeSH terms
-
Anti-Inflammatory Agents / pharmacology
-
Anti-Inflammatory Agents / therapeutic use*
-
Antibodies, Monoclonal / pharmacology
-
Antibodies, Monoclonal / therapeutic use
-
Antibodies, Monoclonal, Humanized
-
Atherosclerosis / drug therapy
-
Atherosclerosis / metabolism
-
Cryopyrin-Associated Periodic Syndromes / drug therapy
-
Humans
-
Hypertension / drug therapy
-
Hypertension / metabolism
-
Interleukin 1 Receptor Antagonist Protein / pharmacology
-
Interleukin 1 Receptor Antagonist Protein / therapeutic use
-
Interleukin-1 / metabolism*
-
Interleukin-1 / therapeutic use
-
Interleukin-1alpha / metabolism
-
Interleukin-1beta / metabolism
-
Kidney Diseases / drug therapy*
-
Kidney Diseases / metabolism
-
Molecular Targeted Therapy
-
Recombinant Fusion Proteins / pharmacology
-
Recombinant Fusion Proteins / therapeutic use
-
Recombinant Proteins / therapeutic use
Substances
-
Anti-Inflammatory Agents
-
Antibodies, Monoclonal
-
Antibodies, Monoclonal, Humanized
-
Interleukin 1 Receptor Antagonist Protein
-
Interleukin-1
-
Interleukin-1alpha
-
Interleukin-1beta
-
Recombinant Fusion Proteins
-
Recombinant Proteins
-
canakinumab
-
rilonacept